ORPHA:3453
Autoimmune polyendocrinopathy type 1
Also known as: APECED syndrome · APS type 1 · APS1 · Autoimmune hypoparathyroidism-chronic candidiasis-Addison disease syndrome · Autoimmune polyendocrine syndrome type 1 · Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome · Autoimmune polyglandular syndrome type 1 · HAM syndrome · Hypoparathyroidism-Addison disease-mucocutaneous candidiasis syndrome · MEDAC syndrome · Multiple endocrine deficiency-Addison disease-candidiasis syndrome
Publications
2,283
94.2th percentile
Trials
7
Interventional, condition-specific
Researchers
1,170
Distinct authors in sample
Gene link
AIRE
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic, disease that manifests in childhood or early adolescence with a combination of chronic mucocutaneous candidiasis, hypoparathyroidism and autoimmune adrenal failure.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009411
- OMIM:240300
- UMLS:C0085859
- NCIT:C129727
Additional Mondo synonyms (16)
AIRE autoimmune polyendocrinopathy · Autoimmune Polyglandular Syndrome Type 1 · Whitaker syndrom · aire autoimmune polyendocrinopathy · autoimmune hypoparathyroidism-chronic candidiasis-Addison disease syndrome · autoimmune polyendocrine syndrome type 1 · autoimmune polyendocrinopathy caused by mutation in AIRE · autoimmune polyendocrinopathy caused by mutation in aire · autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia · autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy · autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome · autoimmune polyglandular syndrome type 1 · ham syndrome · hypoparathyroidism-Addison disease-mucocutaneous candidiasis syndrome · multiple endocrine deficiency-Addison disease-candidiasis syndrome · polyglandular autoimmune syndrome type 1
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — AIRE
- LiteraturePresent
2,283 matched papers (1,351 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
7 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (AIRE).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,283
2,283 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,283 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,351 in the last 10 years · medium confidence · 94.2th percentile (publications denominator)
Phrase hits: 2,283 · MeSH hits: 0
Who's working on it?
1,170
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Lionakis MS26 papers · 2026
Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Papers in Europe PMC - 02Laakso S11 papers · 2026
Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Stenbäckinkatu 9, Helsinki, Finland. saila.laakso@helsinki.fi.
Papers in Europe PMC - 03Ferré EMN10 papers · 2024
Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Papers in Europe PMC - 04Mäkitie O10 papers · 2026
Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Stenbäckinkatu 9, Helsinki, Finland.
Papers in Europe PMC - 05Schmitt MM8 papers · 2026
Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.
Papers in Europe PMC - 06Oftedal BE7 papers · 2026
Department of Clinical Science, Department of Medicine, University of Bergen, Bergen, Norway.
Papers in Europe PMC - 07Betterle C6 papers · 2026
Endocrine Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Papers in Europe PMC - 08Husebye ES6 papers · 2026
Department of Clinical Science, Department of Medicine, University of Bergen, Bergen, Norway.
Papers in Europe PMC - 09Pechacek J6 papers · 2026
Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Papers in Europe PMC - 10Wolff ASB6 papers · 2026
Department of Clinical Science, Department of Medicine, University of Bergen, Bergen, Norway.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
7
interventional trials for this specific condition
7 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 27 July 2026
7 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89.9th percentile).
medium confidence · 89.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
7 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07202598·RECRUITING·Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
Conditions: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis·Matched via name phrase
- NCT05398809·RECRUITING·Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Conditions: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced) · Alopecia Areata·Matched via name phrase
Broader category: autoimmune polyendocrinopathy
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06941584·RECRUITING·Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies
Conditions: AIRE Deficiency·Matched via recall expansion
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Autoimmune polyendocrinopathy type 1" OR "APECED syndrome" OR "APS type 1" OR "Autoimmune hypoparathyroidism-chronic candidiasis-Addison disease syndrome" OR "Autoimmune polyendocrine syndrome type 1" OR "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome" OR "Autoimmune polyglandular syndrome type 1" OR "HAM syndrome" OR "Hypoparathyroidism-Addison disease-mucocutaneous candidiasis syndrome" OR "MEDAC syndrome" OR "Multiple endocrine deficiency-Addison disease-candidiasis syndrome" OR "AIRE autoimmune polyendocrinopathy" OR "Whitaker syndrom" OR "autoimmune polyendocrinopathy caused by mutation in AIRE" OR "autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia" OR "autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy" OR "polyglandular autoimmune syndrome type 1"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autoimmune polyendocrinopathy type 1" OR "APECED syndrome" OR "APS type 1" OR "Autoimmune hypoparathyroidism-chronic candidiasis-Addison disease syndrome" OR "Autoimmune polyendocrine syndrome type 1" OR "Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome" OR "Autoimmune polyglandular syndrome type 1" OR "HAM syndrome" OR "Hypoparathyroidism-Addison disease-mucocutaneous candidiasis syndrome" OR "MEDAC syndrome" OR "Multiple endocrine deficiency-Addison disease-candidiasis syndrome" OR "AIRE autoimmune polyendocrinopathy" OR "Whitaker syndrom" OR "autoimmune polyendocrinopathy caused by mutation in AIRE" OR "autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia" OR "autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy" OR "polyglandular autoimmune syndrome type 1" OR "AIRE"
Recall-expansion terms: AIRE
Interventional trials matched via: phrase, recall-expansion (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 7 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"autoimmune polyendocrinopathy"
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: APS1
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T23:13:55.186Z
